
- 1D
- 1W
- 1M
- 1Y
- 5Y
- YTD
About Pharvaris
Pharvaris B.V. operates as a clinical-stage company. The Company focuses on the discovery and development of novel oral B2-receptor antagonists for the treatment of patients. Pharvaris serves customers in the Netherlands and Switzerland.
News
Stock Analysis

last close
$17.02
1-mo return
-27.3%
3-mo return
4.1%
avg daily vol.
4.81T
52-week high
27.5
52-week low
13.14
market cap.
$630M
forward pe
-
annual div.
-
roe
-25.1%
ltg forecast
-
dividend yield
-
annual rev.
$--
inst own.
76.1%